GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artiva Biotherapeutics Inc (NAS:ARTV) » Definitions » Insider Ownership

ARTV (Artiva Biotherapeutics) Insider Ownership : 1.67 % (As of Dec. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Artiva Biotherapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Artiva Biotherapeutics's insider ownership is 1.67%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Artiva Biotherapeutics's Institutional Ownership is 85.23%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Artiva Biotherapeutics's Float Percentage Of Total Shares Outstanding is 99.39%.


Artiva Biotherapeutics Insider Ownership Historical Data

The historical data trend for Artiva Biotherapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artiva Biotherapeutics Insider Ownership Chart

Artiva Biotherapeutics Historical Data

The historical data trend for Artiva Biotherapeutics can be seen below:

2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Insider Ownership 1.08 1.04 1.67 1.67 1.67

Artiva Biotherapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Artiva Biotherapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.